Open-label therapeutic trials of biologics in primary Sjögren’s disease reported between 2002 and 2014.

N, number of patients; pSS, primary Sjögren’s syndrome; AECG: American-European Consensus Group criteria for primary Sjögren’s syndrome; SGB, salivary-gland biopsy; Ig, immunoglobulin; MALT, mucosa-associated lymphoid tissue; ESR, erythrocyte sedimentation rate; VAS, visual analogue scale (0–100 mm); RF, rheumatoid factor; MFI, Multidimensional Fatigue Inventory; C4, fraction 4 of complement; ESSDAI, European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patient Reported Index; SF-36, Short-Form 36-item quality of life questionnaire; SGUS, salivary-gland ultrasound; NA, not applicable; BELISS: Belimumab in primary Sjögren’s SyndromeOpen-label therapeutic trials of biologics in primary Sjögren’s disease reported between 2002 and 2014.